Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Clinigen Group Plc (CLIN.LN)

Clinigen Group Plc (CLIN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Clinigen Group Plc Pitcairn House, Crown Square First Avenue, Centrum 100 Burton-on-Trent DE14 2WW GBR

https://www.clinigengroup.com P: 128-349-5010 F: 128-349-5011

Description:

Clinigen Group PLC is a global pharmaceutical and health-services company that operates in three areas of global medicine supply: clinical trials, unlicensed medicines, and licensed medicines. The vast majority of the company's revenue is derived from unlicensed medicine activities, followed by licensed medicines. The bulk of Clinigen's profit is generated in European regions and the United States. The company maintains a presence in emerging markets around the world, where recent activities have focused on widening customer bases while addressing concerns surrounding counterfeit medicines.

Key Statistics

Overview:

Market Capitalization, $K 1,233,645
Shares Outstanding, K 133,367
Annual Sales, $ 523,600 K
Annual Net Income, $ 30,300 K
% of Insider Shareholders 3.77%
% of Institutional Shareholders 32.24%

Growth:

1-Year Return 15.91%
3-Year Return -3.55%
5-Year Return 16.35%
5-Year Revenue Growth 9.03%
5-Year Earnings Growth 13.58%
5-Year Dividend Growth 16.15%

Per-Share Information:

Latest Earnings Date N/A
Earnings Per Share ttm 0.14
EPS Growth vs. Prev Year 1.19%
Annual Dividend Rate, $ 0.08
Annual Dividend Yield 0.82%
Most Recent Dividend 0.055 on 12/02/21
Next Ex-Dividends Date 12/02/21
Dividend Payable Date 01/04/22
Dividend Payout Ratio 36.76%

CLIN.LN Ratios

Ratio
Price/Earnings ttm 44.69
Price/Earnings forward 15.31
Return-on-Equity % 4.37%
Return-on-Assets % 1.88%
Profit Margin % 5.79%
Debt/Equity 0.93
Price/Sales 2.23
Price/Book 2.71
Book Value/Share 3.41
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar